PL1879585T3 - Zastosowanie pochodnych pirymidyloaminobenzamidowych do leczenia mastocytozy układowej - Google Patents
Zastosowanie pochodnych pirymidyloaminobenzamidowych do leczenia mastocytozy układowejInfo
- Publication number
- PL1879585T3 PL1879585T3 PL06751956T PL06751956T PL1879585T3 PL 1879585 T3 PL1879585 T3 PL 1879585T3 PL 06751956 T PL06751956 T PL 06751956T PL 06751956 T PL06751956 T PL 06751956T PL 1879585 T3 PL1879585 T3 PL 1879585T3
- Authority
- PL
- Poland
- Prior art keywords
- pyrimidylamimobenzamide
- derivatives
- treatment
- systemic mastocytosis
- mastocytosis
- Prior art date
Links
- 201000008736 Systemic mastocytosis Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67674005P | 2005-05-02 | 2005-05-02 | |
| PCT/US2006/016541 WO2006119154A1 (en) | 2005-05-02 | 2006-05-01 | Use of pyrimidylamimobenzamide derivatives for the treatment of systematic mastocytosis |
| EP06751956.1A EP1879585B1 (en) | 2005-05-02 | 2006-05-01 | Use of pyrimidylamimobenzamide derivatives for the treatment of systemic mastocytosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1879585T3 true PL1879585T3 (pl) | 2013-08-30 |
Family
ID=36867557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06751956T PL1879585T3 (pl) | 2005-05-02 | 2006-05-01 | Zastosowanie pochodnych pirymidyloaminobenzamidowych do leczenia mastocytozy układowej |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20080176879A1 (pl) |
| EP (1) | EP1879585B1 (pl) |
| JP (1) | JP5129123B2 (pl) |
| KR (1) | KR101376875B1 (pl) |
| CN (2) | CN103638028A (pl) |
| AU (1) | AU2006242311B2 (pl) |
| BR (1) | BRPI0609296A2 (pl) |
| CA (1) | CA2606716C (pl) |
| ES (1) | ES2421587T3 (pl) |
| MX (1) | MX2007013741A (pl) |
| PL (1) | PL1879585T3 (pl) |
| PT (1) | PT1879585E (pl) |
| RU (1) | RU2445960C2 (pl) |
| WO (1) | WO2006119154A1 (pl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1686997E (pt) * | 2003-11-18 | 2009-07-17 | Novartis Ag | Inibidores da forma mutante de kit |
| EP2152079A4 (en) | 2007-06-04 | 2011-03-09 | Avila Therapeutics Inc | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| JO3634B1 (ar) * | 2009-11-17 | 2020-08-27 | Novartis Ag | طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r |
| CN107001214B (zh) | 2014-12-26 | 2021-03-23 | 花王株式会社 | 环状二酮化合物的制造方法 |
| US11065230B2 (en) * | 2016-09-16 | 2021-07-20 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of systemic mastocytosis |
| CN120305263A (zh) | 2018-06-15 | 2025-07-15 | 汉达癌症医药责任有限公司 | 卡博替尼的盐类于制备治疗癌症的剂型的用途 |
| KR102535842B1 (ko) | 2020-07-31 | 2023-05-23 | (주)파로스아이바이오 | 2,3,5-치환된 싸이오펜 화합물의 비만세포증 예방, 개선 또는 치료 용도 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| TW225528B (pl) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| US5543520A (en) | 1993-10-01 | 1996-08-06 | Ciba-Geigy Corporation | Pyrimidine derivatives |
| JPH08503971A (ja) | 1993-10-01 | 1996-04-30 | チバ−ガイギー アクチェンゲゼルシャフト | ピリミジンアミン誘導体及びその調製のための方法 |
| CA2174080A1 (en) * | 1993-10-12 | 1995-04-20 | Paul Edward Aldrich | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| AU7821398A (en) | 1997-06-06 | 1998-12-21 | Baylor College Of Medicine | The mast cell secretory machine as a target for anti-allergy drug development |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| JP2002516820A (ja) | 1997-11-13 | 2002-06-11 | ヒスタテク・エルエルシー | 低分子量ペプチド及び喘息及び炎症の治療方法 |
| US20040157855A1 (en) | 2001-04-05 | 2004-08-12 | Michael Heinrich | Use of n-phenyl-2-pyrimidineamine derivativea against mast cell-based diseases like allergic disorders |
| GB0108606D0 (en) * | 2001-04-05 | 2001-05-23 | Novartis Ag | Organic compounds |
| US20050054617A1 (en) * | 2001-06-29 | 2005-03-10 | Alain Moussy | Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis |
| TWI315982B (en) | 2001-07-19 | 2009-10-21 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
| US20050095237A1 (en) * | 2001-12-11 | 2005-05-05 | Emtage Peter C. | Methods of therapy and diagnosis using targeting of cells that express P2Y10 |
| EP1483401A1 (en) | 2002-03-13 | 2004-12-08 | F.Hoffmann-La Roche Ag | Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors |
| JP2005508846A (ja) * | 2002-04-05 | 2005-04-07 | ノバルティス アクチエンゲゼルシャフト | アレルギー性疾患のような肥満細胞系疾患に対するｎ−フェニル−２−ピリミジンアミン誘導体の使用 |
| JP4032140B2 (ja) * | 2002-07-02 | 2008-01-16 | 大原商事株式會社 | つけ爪の取り付け方法 |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| GB0223341D0 (en) | 2002-10-08 | 2002-11-13 | Groningen Acad Ziekenhuis | Organic compounds |
| TWI324604B (en) | 2003-06-18 | 2010-05-11 | Novartis Ag | New use of staurosporine derivatives |
| CN100467064C (zh) | 2003-09-19 | 2009-03-11 | 诺瓦提斯公司 | 伊马替尼和米哚妥林在制备治疗胃肠道基质肿瘤药物中的应用 |
| PT1686997E (pt) | 2003-11-18 | 2009-07-17 | Novartis Ag | Inibidores da forma mutante de kit |
-
2006
- 2006-05-01 CN CN201310652355.4A patent/CN103638028A/zh active Pending
- 2006-05-01 PL PL06751956T patent/PL1879585T3/pl unknown
- 2006-05-01 ES ES06751956T patent/ES2421587T3/es not_active Expired - Lifetime
- 2006-05-01 WO PCT/US2006/016541 patent/WO2006119154A1/en not_active Ceased
- 2006-05-01 RU RU2007144530/04A patent/RU2445960C2/ru not_active IP Right Cessation
- 2006-05-01 EP EP06751956.1A patent/EP1879585B1/en not_active Expired - Lifetime
- 2006-05-01 JP JP2008510093A patent/JP5129123B2/ja not_active Expired - Fee Related
- 2006-05-01 AU AU2006242311A patent/AU2006242311B2/en not_active Ceased
- 2006-05-01 BR BRPI0609296-9A patent/BRPI0609296A2/pt not_active IP Right Cessation
- 2006-05-01 CA CA2606716A patent/CA2606716C/en not_active Expired - Fee Related
- 2006-05-01 PT PT67519561T patent/PT1879585E/pt unknown
- 2006-05-01 CN CNA2006800149433A patent/CN101171013A/zh active Pending
- 2006-05-01 US US11/911,575 patent/US20080176879A1/en not_active Abandoned
- 2006-05-01 KR KR1020077025364A patent/KR101376875B1/ko not_active Expired - Fee Related
- 2006-05-01 MX MX2007013741A patent/MX2007013741A/es active IP Right Grant
-
2010
- 2010-04-29 US US12/769,734 patent/US8673930B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| RU2445960C2 (ru) | 2012-03-27 |
| US20080176879A1 (en) | 2008-07-24 |
| PT1879585E (pt) | 2013-07-23 |
| KR101376875B1 (ko) | 2014-03-27 |
| US8673930B2 (en) | 2014-03-18 |
| CN101171013A (zh) | 2008-04-30 |
| AU2006242311B2 (en) | 2010-03-04 |
| JP2008540420A (ja) | 2008-11-20 |
| CA2606716C (en) | 2013-07-23 |
| US20100210673A1 (en) | 2010-08-19 |
| CN103638028A (zh) | 2014-03-19 |
| JP5129123B2 (ja) | 2013-01-23 |
| EP1879585A1 (en) | 2008-01-23 |
| ES2421587T3 (es) | 2013-09-04 |
| RU2007144530A (ru) | 2009-06-10 |
| MX2007013741A (es) | 2008-01-21 |
| AU2006242311A1 (en) | 2006-11-09 |
| CA2606716A1 (en) | 2006-11-09 |
| WO2006119154A1 (en) | 2006-11-09 |
| KR20080004563A (ko) | 2008-01-09 |
| EP1879585B1 (en) | 2013-04-17 |
| BRPI0609296A2 (pt) | 2010-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200706791B (en) | Isoxazole combretasin derivatives for the treatment of disorders | |
| IL191832A0 (en) | Pyridiazinone derivatives for the treatment of tumours | |
| IL184934A0 (en) | 4-oxoquinazoline-3-yl-benzamide derivatives for the treatment of cytokine diseases | |
| AP2007004157A0 (en) | N- (N-sulfonylaminomethyl) cyclo-propanecarboxamide derivatives useful for the treatment of pain | |
| IL195906A0 (en) | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | |
| AP2006003671A0 (en) | Sulfonamide derivatives for the treatment of diseases | |
| IL188390A0 (en) | Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders | |
| ZA201001264B (en) | 1-amino-alkylcycohxane derivatives for the treatment of cochleat tinnitus | |
| AP2006003669A0 (en) | Sulfonamide derivatives for the treatment of diseases | |
| ZA200805159B (en) | Imidazole derivatives for the treatment of gastrointestinal disorders | |
| IL177232A0 (en) | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | |
| IL213474A0 (en) | Processes for the preparation of cyclopropyl-amide derivatives | |
| IL192933A0 (en) | Benzoisoindole derivatives for the treatment of pain | |
| EP1893625A4 (en) | PROCESS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES | |
| PL1959957T3 (pl) | Pochodne pirymidyloaminobenzamidu do leczenia neurowłókniakowatości | |
| EP1750698A4 (en) | 5-ANILINO-4-HETEROARYLPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | |
| ZA200800921B (en) | Pyrazolone derivatives for the treatment of tuberculosis | |
| IL178907A0 (en) | Use of sulglicotide for the treatment of mucositis | |
| PL1727545T3 (pl) | Zastosowanie pochodnych N-piperydyny do leczenia patologii neurodegeneracyjnych | |
| ZA200800409B (en) | Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders | |
| ZA200706203B (en) | Processes and compounds for the preparation of substituted naphthylindole derivatives | |
| ZA200608015B (en) | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | |
| ZA200806180B (en) | Benzoisoindole derivatives for the treatment of pain | |
| EP1956001A4 (en) | PHARMACEUTICAL PRODUCT FOR USE IN THE TREATMENT OF URETEROLITHIASE | |
| GB0406387D0 (en) | Sulfonamide derivatives for the treatment of diseases |